These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 30189902)

  • 1. Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trials.
    Schultz NM; Shore ND; Chowdhury S; Klotz LH; Concepcion RS; Penson DF; Karsh LI; Yang H; Brown BA; Barlev A; Flanders SC
    BMC Urol; 2018 Sep; 18(1):77. PubMed ID: 30189902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study.
    Shore ND; Chowdhury S; Villers A; Klotz L; Siemens DR; Phung D; van Os S; Hasabou N; Wang F; Bhattacharya S; Heidenreich A
    Lancet Oncol; 2016 Feb; 17(2):153-163. PubMed ID: 26774508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial.
    Penson DF; Armstrong AJ; Concepcion R; Agarwal N; Olsson C; Karsh L; Dunshee C; Wang F; Wu K; Krivoshik A; Phung D; Higano CS
    J Clin Oncol; 2016 Jun; 34(18):2098-106. PubMed ID: 26811535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Enzalutamide vs Bicalutamide in Younger and Older Patients with Metastatic Castration Resistant Prostate Cancer in the TERRAIN Trial.
    Siemens DR; Klotz L; Heidenreich A; Chowdhury S; Villers A; Baron B; van Os S; Hasabou N; Wang F; Lin P; Shore ND
    J Urol; 2018 Jan; 199(1):147-154. PubMed ID: 28827103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Enzalutamide Compared with Bicalutamide on Quality of Life in Men with Metastatic Castration-resistant Prostate Cancer: Additional Analyses from the TERRAIN Randomised Clinical Trial.
    Heidenreich A; Chowdhury S; Klotz L; Siemens DR; Villers A; Ivanescu C; Holmstrom S; Baron B; Wang F; Lin P; Shore ND
    Eur Urol; 2017 Apr; 71(4):534-542. PubMed ID: 27497762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: the OCUU-CRPC study.
    Iguchi T; Tamada S; Kato M; Yasuda S; Machida Y; Ohmachi T; Ishii K; Iwata H; Yamamoto S; Kanamaru T; Morimoto K; Hase T; Tashiro K; Harimoto K; Deguchi T; Adachi T; Iwamoto K; Takegaki Y; Nakatani T
    Int J Clin Oncol; 2020 Mar; 25(3):486-494. PubMed ID: 31564004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial.
    Penson DF; Armstrong AJ; Concepcion RS; Agarwal N; Olsson CA; Karsh LI; Dunshee CJ; Duggan W; Shen Q; Sugg J; Haas GP; Higano CS
    Prostate Cancer Prostatic Dis; 2022 Feb; 25(2):363-365. PubMed ID: 34621011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Efficacy of Enzalutamide vs Bicalutamide Combined With Androgen Deprivation Therapy in Men With Metastatic Hormone-Sensitive Prostate Cancer: A Randomized Clinical Trial.
    Vaishampayan UN; Heilbrun LK; Monk P; Tejwani S; Sonpavde G; Hwang C; Smith D; Jasti P; Dobson K; Dickow B; Heath EI; Semaan L; Cher ML; Fontana JA; Chinni S
    JAMA Netw Open; 2021 Jan; 4(1):e2034633. PubMed ID: 33496795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomised, double-blind study comparing the addition of bicalutamide with or without dutasteride to GnRH analogue therapy in men with non-metastatic castrate-resistant prostate cancer.
    Chu FM; Sartor O; Gomella L; Rudo T; Somerville MC; Hereghty B; Manyak MJ
    Eur J Cancer; 2015 Aug; 51(12):1555-69. PubMed ID: 26048455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
    BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The addition of bicalutamide 150 mg to radiotherapy significantly improves overall survival in men with locally advanced prostate cancer.
    See WA; Tyrrell CJ;
    J Cancer Res Clin Oncol; 2006 Aug; 132 Suppl 1():S7-16. PubMed ID: 16896884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiandrogens Inhibit ABCB1 Efflux and ATPase Activity and Reverse Docetaxel Resistance in Advanced Prostate Cancer.
    Zhu Y; Liu C; Armstrong C; Lou W; Sandher A; Gao AC
    Clin Cancer Res; 2015 Sep; 21(18):4133-42. PubMed ID: 25995342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determination of enzalutamide long-term safety and efficacy for castration-resistant prostate cancer patients after combined anti-androgen blockade followed by alternative anti-androgen therapy: a multicenter prospective DELC study.
    Nagahara A; Uemura M; Sato M; Nakata W; Tsujihata M; Takao T; Matsumura S; Nishimura K; Takada S; Iwanishi T; Kobayashi Y; Ishizuya Y; Takada T; Okada K; Inoue H; Kato T; Hatano K; Kawashima A; Ujike T; Fujita K; Nonomura N
    Jpn J Clin Oncol; 2024 May; 54(5):584-591. PubMed ID: 38305451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enzalutamide in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Asian Multiregional, Randomized Study.
    Pu YS; Ahn H; Han W; Huang SP; Wu HC; Ma L; Yamada S; Suga K; Xie LP
    Adv Ther; 2022 Jun; 39(6):2641-2656. PubMed ID: 35397772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer.
    Bales GT; Chodak GW
    Urology; 1996 Jan; 47(1A Suppl):38-43; discussion 48-53. PubMed ID: 8560677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate cancer: Enzalutamide is superior to bicalutamide for mCRPC.
    Sidaway P
    Nat Rev Urol; 2016 Mar; 13(3):124. PubMed ID: 26832166
    [No Abstract]   [Full Text] [Related]  

  • 17. Enzalutamide in patients with non-metastatic castration-resistant prostate cancer after combined androgen blockade for recurrence following radical treatment in Japan (Japanese research for patients with non-metastatic castration-resistant prostate cancer-enzalutamide: JCASTRE-zero)-a prospective single-arm interventional study.
    Sugimoto M; Kato T; Tohi Y; Shimizu Y; Matsumoto R; Inoue T; Takezawa Y; Masui K; Sasaki H; Hirama H; Saito S; Egawa S; Kamoto T; Teramukai S; Kojima S; Kikuchi T; Kakehi Y
    BMC Urol; 2022 Sep; 22(1):151. PubMed ID: 36104667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prior switching to a second-line nonsteroidal antiandrogen does not impact the therapeutic efficacy of abiraterone acetate in patients with metastatic castration-resistant prostate cancer: a real-world retrospective study.
    Zhao JG; Liu JD; Shen PF; Tang X; Sun GX; Zhang XM; Chen JR; Shu KP; Shi M; Zeng H
    Asian J Androl; 2018; 20(6):545-550. PubMed ID: 30106011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Salvage therapy with bicalutamide 150 mg in nonmetastatic castration-resistant prostate cancer.
    Lodde M; Lacombe L; Fradet Y
    Urology; 2010 Nov; 76(5):1189-93. PubMed ID: 20303155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: study protocol for a multicenter randomized phase II trial (the OCUU-CRPC study).
    Iguchi T; Tamada S; Kato M; Yasuda S; Yamasaki T; Nakatani T
    BMC Cancer; 2019 Apr; 19(1):339. PubMed ID: 30971225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.